Cadrenal Therapeutics appoints Dr. Lee Golden to Board of Directors

Cadrenal Therapeutics, Inc.

Dr. Lee Scott Golden appointed independent Class II director effective Nov 24, 2025; term expires at 2027 annual meeting.
Golden is EVP and CMO of PTC Therapeutics (PTCT) with 25+ years in cardiovascular and hematologic drug development.
Golden serves on Science and Technology Committee; receives $35,000 annual fee plus equity awards.
Appointment aligns with Cadrenal's focus on advancing tecarfarin for anticoagulation unmet needs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.